Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
A review of chlamydia and gonorrhea prevention studies conducted by the Regenstrief Institute found that rates of presumptive treatment (antibiotics before diagnosis) varied.
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
More Evidence Ties Microplastics to Lung Cancer
2.
Video: Liver transplant for patients with advanced colorectal cancer
3.
How Much of a Cancer Drug Is Too Much?
4.
Palliative Care Remains Uncommon in Young Adults With Cancer
5.
Revolutionary Cancer Tx Could Transform Autoimmune Disease
1.
Molecular Mechanisms of Tumor Extracellular-Matrix Stiffness Sensing
2.
How to Manage Dic with the Right Treatment Approach
3.
The Immune Revolution: Neoantigen Vaccines and the Dawn of Personalized Cancer Therapy in 2025
4.
Blood-Cell Morphology Foundation Models: Transforming Hematological Diagnostics and Clinical Practice
5.
Essential Oncology Tools: Risk Assessment, Telehealth, AI, and Monitoring
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
3.
Should We Use DARA Up Front As First-Line Therapy in MM? - Part II
4.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
5.
Blood Clotting Disorders Explained
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge